Previous studies evaluating the angiotensin converting enzyme (ACE) gene insertion/deletion (I/ D) polymorphism have revealed that expression of the DD genotype is associated with an increase in myocardial infarction, cardiomyopathy, and left ventricular (LV) mass in nondiabetic patients. In the present study, a cross-sectional analysis was performed to evaluate the potential relationship between the ACE I/D genotypes and the LV mass index in 289 non-insulin-dependent diabetes mellitus (NIDDM) subjects without known coronary artery disease. Two dimensional directed M-mode echocardiograms along with selected patient characteristics were obtained from the study population. The distribution of the I/D polymorphism was as follows: 63 were II (22%), 137 were ID (47%), and 89 were DD (31%). Univariately, the DD genotype was associated with an increase in LV mass in men but not in women. When subjected to a multiple regression model that included age, systolic blood pressure, duration of diabetes, duration of hypertension, presence of the black race, and the presence of the DD genotype, the DD genotype was independently associated with an increase in the LV mass index with a parameter estimate of 10.5 g/m 2 (95% CI ‫؍‬ ‫؍‬ 3.9, 17.0; P < < .002) in the male subjects. Thus, in this NIDDM study population, male patients with the DD genotype are independently associated with an increased LV mass. Am J Hypertens 1999;12:637-642
T ype 2 diabetes mellitus accounts for approximately 90% of the 15 million diabetic patients in this country, 1 with the leading cause of mortality being cardiovascular disease. 2 Up to 60% of patients with type 2 diabetes have a previous diagnosis of hypertension. Nielson et al have demonstrated that diabetic patients a have higher likelihood of left ventricular hypertrophy (LVH) as measured by left ventricular (LV) mass than subjects without diabetes. 3 LVH appears to be a powerful predictor of cardiac morbidity and mortality in nondiabetic populations. 4, 5 In the Framingham Heart Study, incremental increases in LV mass was associated with an increased risk for cardiovascular events in both men and women without diabetes. 6 Verdecchia et al had demonstrated in a population with essential hypertension that a reduction in LV mass predicts a lesser risk for cardiovascular events. 7 However, there is little information about the significance of LVH in type 2 diabetes. 8 Recently the DD genotype of the angiotensin converting enzyme (ACE) gene has been associated with dilated cardiomyopathy 9 and ischemic heart disease. 10 The DD genotype has also been associated with an increase in LV mass in nondiabetic subjects with and without hypertension. [11] [12] [13] In this regard, Rigat et al have demonstrated that the angiotensin converting enzyme (ACE) gene accounts for over half of the variability in circulating ACE levels. 14 Gharavi et al 11 and Lechin et al 15 have postulated that this difference in circulating ACE levels and the subsequent production of angiotensin II may be the reason for the increase in LV mass seen in patients with the DD genotype. The present study was therefore conducted on 289 type 2 diabetic patients who underwent a screening test to determine their ACE genotype to examine the relationship between the ACE gene polymorphism and LV mass in type 2 diabetes.
METHODS

Study Population
The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial is a randomized, prospective, blinded clinical trial designed to determine the effects of moderate versus intensive antihypertensive control on the outcome of diabetic complications in type 2 diabetes. The ABCD Trial has been described previously. 16 Subjects in the ABCD Trial were between the ages of 40 and 74 years and were identified from Diagnosis Related Group (DRG), pharmacy, and billing lists from participating hospitals from March 1991 through January 1993. All patients enrolled in the ABCD Trial were diagnosed with type 2 diabetes according to the criteria based upon the World Health Organization report of 1985, 17 which followed the National Diabetes Group criteria of 1979.
Genomic DNA Preparation Genomic DNA was extracted from peripheral blood as described previously. 9 Genomic DNA was extracted from leukocytes in dried blood spots collected on filter paper. Spots were excised using sterile biopsy punches, placed into microfuge tubes, and incubated at 56°C for 18 hours in lysis buffer (154 mmol/L NaCl, 10 mmol/L Tris-HCl pH 7.5, 1 mmol/L NaEDTA, pH 8.0, 5% proteinase K, 1% sodium dodecyl sulfate [SDS] ). Proteins were removed by sequential phenol-chloroform and chloroform extraction. DNA was precipitated from the aqueous phase by addition of 1/10 volume 3 mmol/L sodium acetate (pH 5.0) and an equal volume of icecold isopropanol. Samples were held at Ϫ20°C overnight, and genomic DNA was collected by centrifugation.
Polymerase Chain Reaction (PCR) Amplification of the ACE Polymorphism The polymorphic region of the angiotensin converting enzyme intron 16, consisting of the presence (I) or absence (D) of a 287 bp alu repeat sequence, was amplified from genomic DNA by PCR. The oligonucleotide primers used in the reaction were as previously published. 14, 18 Approximately 500 ng to 1 g of genomic DNA was used per reaction, and the reaction conditions were as previously published. 9 The ACE genotype of each study participant was scored based on resolution of PCR products by gel electrophoresis. 
Assessment of Blood Pressure
Blood pressure measurements were taken 8 to 11 weeks after the cessation of preexisting antihypertensive medications during the prerandomization placebo run-in period. Three blood pressure measurements were taken 2 min apart in the sitting position using a standard mercury sphygmomanometer at the randomization visit. The mean of these three measurements was used for analysis. Diastolic blood pressure (DBP) was defined as the disappearance of the last Korotkoff sound and systolic blood pressure (SBP) was defined as the first Korotkoff sound. All study nurses passed a standardized examination and are certified annually in the methods of obtaining proper blood pressure measurements by Shared Care, Inc. (Englewood, CO). The recommendations for obtaining blood pressure measurements made by the American Heart Association (AHA) were used in the conduct of the ABCD Trial.
Echocardiographic Methods Subjects were studied using a standard M-mode echocardiographic technique. Measurements of the LV were performed at end-diastole, according to the Penn Convention. 19 LV mass was determined by the following equation used in conjunction with Penn convention measurements: LV mass (g) ϭ 1.04 [(LVID ϩ VST ϩ PWT) 3 Ϫ (LVID) 3 ] Ϫ 13.6, where LVID ϭ LV internal diameter, VST ϭ ventricular septal thickness, and PWT ϭ posterior wall thickness. LV mass was then corrected for height squared.
Statistical Analysis
The Statistical Analysis Software (SAS) system was used for all statistical analyses. Men and women were analyzed separately. When looking for differences in baseline characteristics across the three levels of genotype, two statistical pro-cedures were used. When the baseline characteristic was continuous (age, body mass index, glycosylated hemoglobin, DBP, SBP, and LV mass index) an analysis of variance (ANOVA) was used. 2 Analyses were used when the baseline characteristics were categorical (race/ethnicity). Multiple regression analyses were employed when evaluating the effect(s) of a continuous or categorical covariate(s) on LV mass index. Odds ratios and their corresponding confidence intervals were then calculated from the logistic regression parameter estimates.
RESULTS
Patient Characteristics
Of the 608 ABCD Trial subjects without a history of coronary artery disease who had ACE genotype determinations, 289 had technically interpretable echocardiograms. Echocardiograms were considered not interpretable secondary to poor quality of images, which was caused by a thick chest wall or an angle of the heart not allowing an adequate M-mode measurement. These type 2 diabetic patients were quite obese, thus increasing the percentage of echocardiograms that were not interpretable. The distribution of the genotypes was similar between the subjects included (II ϭ 22%, IC ϭ 47%, and DD 31%) and those excluded (II ϭ 22%, ID ϭ 48%, and DD 30%). The characteristics of the study population are listed according to the ACE genotype in Table 1 (men) and 1b (women). In the females, patients with the DD genotype were younger than the patients with the II genotype, P Ͻ .004.
Echocardiographic Findings
In the male group, patients with the DD genotype had statistically higher LV mass index than patients with the II and ID genotype, p Ͻ .02, Table 1 . There was no statistically significant differences between the ACE genotypes for the female subjects with regard to LV mass index.
Stepwise multiple regression analyses of LV mass index were then performed using the ACE genotype (ID/II ϭ 0, DD ϭ 1), presence of black race, age, duration of diabetes, and the duration of hypertension. The results are listed in Table 2 . The presence of the DD genotype in the men was statistically associated with an increase in LV mass index with a parameter estimate of 10.5 gm/m 2 , P Ͻ .002. Systolic blood pressure in the men was also independently associated with an increase in the LV mass index. In the women, there was no association between the genotype and LV mass index.
DISCUSSION
An increase in LV mass, when derived from standard M-mode echocardiograms, is a powerful predictor of future cardiovascular events. 4, 6 Subjects with type 2 diabetes suffer from cardiovascular disease at a rate in excess of that predicted by other known cardiovascular risk factors. In the present study of type 2 diabetic subjects, the DD genotype of the ACE gene polymorphism and an increase in systolic blood pressure were independently associated with an increase in the LV mass index in men but not in women. In the multiple regression analyses, the ACE genotype accounted for most of the variability seen with LV mass. These observations may have important implications for the management of male type 2 diabetic patients, as the presence of LVH no doubt is associated with an increase in morbidity and mortality. In previous studies, there have been conflicting data regarding the association between the ACE gene polymorphism and cardiovascular disease in the diabetic and nondiabetic populations. 10, 11, 21, 22 Some studies have demonstrated the association between the ACE genotype and the presence of LVH by electrocardiographic criteria 13 or echocardiographic methods. 11, 23 In contrast, West et al 24 and Lindpainter et al 25 did not demonstrate a relationship using echocardiographic methods. Analysis of the Framingham data by Lindpainter evaluated a large population of mostly nonhypertensive and nondiabetic subjects. West et al evaluated the association between the genotype and LVH from several studies and suggested that the difference in findings may be due to methodologic problems, differences in genetic background between populations, interactions between genetic variants of the renin-angiotensin system, or the statistical model being inappropriate. 26 There are only a few studies comparing the relationship between the ACE genotype and cardiovascular disease in diabetic subjects. Ruiz et al demonstrated an increased relative risk in individuals heterozygous and homozygous for the D allele with regard to the presence of cardiovascular disease. 22 There have been no previous studies in diabetic patients demonstrating the relationship between the ACE gene polymorphism with LV mass. In our patient population with relatively high blood pressures (mean systolic blood pressure of 146 mm Hg and mean diastolic blood pressure of 91 mm Hg), we demonstrated that in the men, the presence of the DD genotype accounted for approximately a 10 g/m 2 increase in the LV mass index.
Although the mechanism by which the ACE genotype might influence LV mass is unknown, the association between the DD genotype and the increased LV mass index may be explained by effects of the renin-angiotensin system. Gharavi et al have suggested that angiotensin II may promote cardiac growth and remodeling not only through blood pressure regulation but also through a local tissue system. 11 The angiotensin converting enzyme promotes the conversion of angiotensin I to angiotensin II. In addition, Sadoshima et al have demonstrated that angiotensin II independently induces hypertrophy of cardiac tissue. 27 Schunkert et al have also demonstrated in an animal model that ACE levels are increased in hypertrophied cardiac tissue that has been exposed to pressure overload. 28 Furthermore, use of ACE inhibitors has been demonstrated to reduce LV mass independent of blood pressure in normotensive and hypertensive rats. 29, 30 Thus, the increased circulating levels of ACE associated with the DD genotype 14 may influence the local tissue concentration of angiotensin II, which in turn increases LV mass. In the present study of type 2 diabetic subjects, the combination of the DD genotype and higher blood pressures may have enhanced angiotensin II activity in cardiac tissue and thereby increased LV mass.
It was interesting that in the present study this association between the ACE genotype and LV mass index was not demonstrated in female subjects with type 2 diabetes. The women with the DD genotype, however, were statistically younger and had a shorter duration of diabetes than their II/ID counterparts and there was also a trend for a lower systolic blood pressure in the group of female subjects with the DD genotype. Thus, at least theoretically, younger age, shorter duration of diabetes, and lower systolic blood pressure in the women with the DD allele could have obscured the effect of this genotype on LV mass.
In conclusion, the results of the present study suggest that men with type 2 diabetes and the DD genotype have an increased risk for developing left ventricular hypertrophy. Systolic blood pressure was also independently associated with increased LV mass index in men with type 2 diabetes. Hence, type 2 diabetic male patients with the DD genotype, especially in combination with systolic hypertension, may be at increased risk for developing left ventricular hypertrophy. These patients therefore warrant close follow-up and aggressive treatment, possibly with ACE inhibitors, as left ventricular hypertrophy is associated with an increased mortality secondary to cardiovascular disease.
